Nivalis Therapeutics Inc. (NASDAQ:NVLS) shares shot up 2.8% during trading on Thursday . The stock traded as high as $6.18 and last traded at $6.16, with a volume of 62,820 shares changing hands. The stock had previously closed at $5.99.

Several research firms have commented on NVLS. Cowen and Company reissued a “buy” rating on shares of Nivalis Therapeutics in a research report on Monday, May 2nd. Zacks Investment Research raised Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research report on Tuesday, July 12th. Finally, HC Wainwright reissued a “buy” rating on shares of Nivalis Therapeutics in a research report on Monday, August 8th.

The firm’s market cap is $99.22 million. The stock has a 50 day moving average price of $5.20 and a 200 day moving average price of $4.68.

Nivalis Therapeutics (NASDAQ:NVLS) last announced its earnings results on Monday, August 1st. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.03. On average, equities research analysts predict that Nivalis Therapeutics Inc. will post ($2.29) EPS for the current year.

In other Nivalis Therapeutics news, CMO David Malcom Rodman sold 5,950 shares of the business’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $4.66, for a total transaction of $27,727.00. Following the sale, the chief marketing officer now directly owns 18,055 shares of the company’s stock, valued at approximately $84,136.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.